How useful is [123I]β-CIT SPECT in clinical practice?

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 9, 2005, Pages 1211-1216

  Eerola, Johanna ^a   Tienari, P J ^a   Kaakkola, S ^a   Nikkinen, P ^a   Launes, J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; IODINE 123; COCAINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DEMENTIA; DEMENTIA WITH LEWY BODIES; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG INDUCED DISEASE; DYSTONIA; ESSENTIAL TREMOR; FEMALE; HUMAN; LEWY BODY; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; NEUROIMAGING; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VASCULAR PARKINSONISM; AGE; CLINICAL TRIAL; MIDDLE AGED; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

AGE FACTORS; AGED; COCAINE; DIAGNOSIS, DIFFERENTIAL; ESSENTIAL TREMOR; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 23944509230     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2004.045237     Document Type: Article

References (44)

1. Chen N, Reith ME. Structure and function of the dopamine transporter. Eur J Pharmacol 2000;405:329-39.
2. 123Ibeta-GT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994;14:982-94.
3. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiologic and clinical implications. N Engl J Med 1988;318:876-80.
4. Fearnley JM, Lees AJ. Aging and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-301.
5. Counihan TJ, Penney JBJ. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains. J Neurol Neurosurg Psychiatry 1998;65:164-9.
6. Ichise M, Kim YJ, Ballinger JR, et al. SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD. J Nucl Med 1997;38:1-6.
7. 123I]β-CIT SPECT visualizes dopamine transporter loss in de novo parkinsonian patients. Eur Neurol 2001;39:44-8.
8. Seibyl JP, Marek KL, Sheff K, et al. Iodine-123-β-CIT and iodine-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998;39:1500-8.
9. Asenbaum S, Brucke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-β-CIT and SPECT in Parkinson's disease. J Nucl Med 1997;38:1-6.
10. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993;90:11965-9.
11. 123I]β-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 2001;16:124-30.
12. 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov Disord 1998;13:438-45.
13. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98.
14. 123I]β-CIT SPECT. J Neurol 1998;245:14-20.
15. 123I-beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-7.
16. 123I]β -CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med 1998;25:1270-6.
17. 123I]β- CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm 1997;50:9-24.
18. 123I]β-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001;16:1023-32.
19. 123I]β-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000;15:1158-67.
20. 123I-β-CIT SPECT: Binding Kinetics and effects of normal aging. J Nucl Med 2000;41:36-44.
21. 123I]β-CIT single photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. Eur J Nucl Med 1997;24:1171-4.
22. van Dyck CH, Seibyl JP, Malison RT. Age-related decline in striatal dopamine transporter binding with iodine-123-β-CIT SPECT. J Nucl Med 1995;36:1175-81.
23. 123I]β-CIT and SPECT. Eur Neurol 2000;43:23-9.
24. 123I-β-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320-5.
25. Ransmayr G, Seppi K, Donnemiller E, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease. Eur J Nucl Med 2001;;28:1523-8.
26. 123I]-β-CIT demonstrates presynaptic nigrostriatal dopaminergic damage in Wilson's disease. J Neurol Neurosurg Psychiatry 1998;65:60-4.
27. 123I]β-CIT single-photon emission computed tomography is normal in dopa-responsive dystonia. Ann Neurol 1998;43:792-800.
28. 123I]β-CIT. Mov Disord 1998;13:319-23.
29. 123I]β-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998;105:1213-28.
30. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
31. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996;47:1113-24.
32. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
33. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-8.
34. Medical Exposure Directive. 1997; 97/43/Euratom.
35. Ahlskog JE, Uitti RJ, O'Connor MK, et al. The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord 1999;14:940-6.
36. 123I]β-CIT. Mov Disord 1999;14:430-42.
37. Guttman M, Stewart D, Hussey D, et al. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-64.
38. 123I-beta-CIT SPECT in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med 1997;24:320-5.
39. 123I]b-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002;17:518-23.
40. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 2004;45:1688-93.
41. 123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001;28:266-72.
42. Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced parkinsonism: an 18F-dopa PET study. Neurology 1993;43:552-6.
43. Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? Mov Disord 2003;18(suppl 7):63-70.
44. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003;184(suppl 1):68-79.